Secondary dyslipidemias and their treatment

Czech version

Authors: V. Soška
Authors‘ workplace: Oddělení klinické biochemie FN u sv. Anny Brno, přednosta doc. MUDr. Vladimír Soška, CSc.
Published in: Vnitř Lék 2007; 53(4): 396-400
Category: Reviews

Overview

Secondary dyslipidemias may develope due to other diseases or due to several important enviromental influences. The most common are secondary dyslipidemias due to following diseases: undercontrolled diabetes mellitus, hypothyreosis, hyperfunction of suprarenal glands, cholestasis, chronic renal diseases (chronic renal failure, nephrotic syndrom), acute infectious diseases. Very common cause of secondary dyslipidemia is abusus of alcohol. Also some drugs may induce dyslipidemias: corticosteroides, immunosupresive drugs, less frequently also thiazid diuretics and non-selective beta-blockers. During pregnancy is dyslipidemia physiologic. If causal treatment of secondary dyslipidemia is possible, hypolipidemic drugs are not indicated. Start of treatment with hypolipidemic drugs depends on the extent of risk of fatal cardiovascular event, not on the blood lipids level. When hypolipidemic treatment is indicated, the choice of the drug and it´s dose depends also on the type od primary disease and it´s severity.

Key words:
secondary dyslipidemia - diabetes mellitus - hypothyreosis - steatosis hepatis - chronic renal failure - immunosupressive drugs - alcohol

Sources

1. Soška V. Familiární hypercholesterolemie: Dovedeme ji správně diagnostikovat? Vnitř Lék 2000; 46: 19-23.

2. Howard BV. Lipoprotein metabolism in diabetes mellitus. J Lipid Res 1987; 28: 613-628.

3. Soška V. Dyslipidemie u metabolického syndromu. Vnitř Lék 2005; 51: 77-81.

4. Manzato E, Zambon A, Lapolla A et al. Lipoprotein abnormalities in well-treated type II diabetic patients. Diabetes Care 1993; 16: 469-475.

5. Vaverková H, Soška V, Rosolová H et al. Doporučení pro diagnostiku a léčbu dyslipidemií v dospělosti, vypracované výborem České společnosti pro aterosklerózu. Vnitř Lék 2007; 53: 181-197.

6. Salter AM, Hayashi R, Al-Seeni M et al. Effects of hypothyreoidism and high-fat feedeng on mRNA concentration for the low-density-lipoprotein receptors and on acyl-CoA: cholesterol acyltransferaze activities in rat liver. Biochem J 1991; 276: 825-832.

7. Olšovská V, Šiprová H, Beránek M et al. Vliv dlouhodobé substituční terapie růstovým hormonem na tělesné složení, kostní tkáň a některé metabolické parametry u dospělých osob s deficitem růstového hormonu. Vnitř Lék 2005; 51: 1356-1364.

8. DeBoer H, Blok G, Voerman H et al. A lipid levels in growth hormon-deficient men. Metabolism 1994; 43: 199-203.

9. Miller JP. Liver disease. In: Betteridge DJ, Illingworth DR. Lipoproteins in health and disease. London: Arnold 1999: 985-1009.

10. Toledo FG, Sniderman AD, Kelley DE. Influence of hepatic steatosis (fatty liver) on severity and composition of dyslipidemia in type 2 diabetes. Diabetes Care 2006; 29: 1845-1850.

11. Soška V. Hyperlipoproteinaemia in chronic renal failure: Aethiology and therapy. Klin Biochem Metab 1994; 3: 116-118.

12. Shurraw S, Tonelli M. Statins for treatment of dyslipidemia in chronic kidney disease. Perit Dial Int 2006; 26: 523-539.

13. Szromba C. Dyslipidemias in chronic kidney disease. Nephrol Nurs J 2006; 33: 575-576.

14. Kimak E, Solski J, Baranowicz-Gaszczyk I et al. A long-term study of dyslipidemia and dyslipoproteinemia in stable post-renal transplant patients. Ren Fail 2006; 28: 483-486.

15. Black H. Metabolic considerations in the choice of therapy for the patient with hypertension. Am Heart J 1992; 121: 707-715.

16. Stampfer M, Willett W, Colditz G et al. A prospective study of past use of oral contraceptive agents and risk of cardiovascular diseases. N Engl J Med 1988; 319: 1311-1317.

17. Knopp RH. Cardiovascular effects of endogenous and exogenous sex hormones over a woman´s lifetime. Am J Obstetrics Gynekol 1988; 158: 1630-1643.

18. Glazer G. Atherogenic effects of anabolic steroids on serum lipid levels. Arch Intern Med 1991; 151: 1925-1933.

19. Crouse JR, Grundy SM. Effects of alcohol on plasma lipoproteins and cholesterol and triglyceride metabolism in man. J Lipid Res 1984; 25: 1721-1724.

20. Baraona E, Lieber CS. Alcohol. In: Betteridge DJ, Illingworth DR. Lipoproteins in health and disease. London: Arnold 1999: 1011-1036.

21. Gallin JI, Kaye D, O´Leary WM. Serum lipids in infection. N Engl J Med 1969; 281: 1081-1086.

22. Soška V. Poruchy metabolizmu lipidů. Diagnostika a léčba. 1. vyd. Praha: Grada Publishing 2001.